Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) shares saw strong trading volume on Friday . 2,251,106 shares traded hands during trading, an increase of 187% from the previous session’s volume of 785,150 shares.The stock last traded at $21.73 and had previously closed at $21.73.

Several research analysts have commented on the company. Deutsche Bank AG downgraded Sagent Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th. TheStreet raised Sagent Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 11th. Raymond James Financial Inc. cut Sagent Pharmaceuticals from a “buy” rating to a “market perform” rating in a report on Tuesday, July 12th. Zacks Investment Research upgraded Sagent Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Tuesday, July 12th. Finally, Royal Bank Of Canada cut Sagent Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Monday, July 11th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $18.54.

The company’s market cap is $715.13 million. The company’s 50 day moving average is $21.54 and its 200 day moving average is $15.29.

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.